Marc Davies

Marc Davies received his PhD from the laboratory of Dr John Maher at King’s College London, where his research focussed on the development and pre-clinical assessment of CAR T-cells targeting the extended ErbB family. Following a post-doctoral position at University College London developing CAR T-cells for haematological malignancies, Marc returned to KCL where his research focussed on enhancing CAR T-cell efficacy against solid tumours. With over 15 years’ experience in the field of adoptive cell therapy, Marc joined Leucid Bio in May 2021 as VP of CAR Engineering to manage their burgeoning CAR T-cell R&D pipeline and clinical translation of their lead asset, LEU011.